Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group-Reference-Cited by-同舟云学术

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Published:2015-08-21 Issue:11 Volume:29 Page:2126-2133
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kröger N M,Deeg J H,Olavarria E,Niederwieser D,Bacigalupo A,Barbui T,Rambaldi A,Mesa R,Tefferi A,Griesshammer M,Gupta V,Harrison C,Alchalby H,Vannucchi A M,Cervantes F,Robin M,Ditschkowski M,Fauble V,McLornan D,Ballen K,Popat U R,Passamonti F,Rondelli D,Barosi G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015233.pdf

Reference67 articles.

1. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP . MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011; 35: 12–13.

2. Tefferi A . Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 915–925.

3. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.

4. Dokal I, Jones L, Deenmamode M, Lewis SM, Goldman JM . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1989; 71: 158–160.

5. Gupta V, Hari P, Hoffman R . Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120: 1367–1379.

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review;Hematology;2024-09-13

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study;Blood Advances;2024-08-14

4. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24

5. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02